Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4619612 (State ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2020 Earnings Conference Call February 26, 2021 9:00 AM ET Company Participants Thomas Gad – Chairman Claus Moller – Chief Executive Officer Bo Kruse – Chief Financial Officer Conference Call Participants Alec Stranahan – Bank of America Robert Burns – H.C. Wainwright Paul Jeng – Guggenheim David Lebovitz – Morgan Stanley Tessa Romero – J.P. Morgan Peter Lawson – Barclays Sebastiaan van der Schoot – Kempen & Company Operator Greetings, and welcome to Y-mAbs Fourth ...

mAbs herapeutics, Inc. Company Presentation February 2021 Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans an ...

mAbs herapeutics, Inc. Company Presentation January 2021 Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2020 Earnings Conference Call November 6, 2020 9:00 AM ET Company Participants Thomas Gad - Chairman of the Board, President, Founder, Head of Business Development & Strategy Claus Moller - Chief Executive Officer Bo Kruse - Chief Financial Officer, Treasurer & Secretary Conference Call Participants Robert Burns - H.C. Wainwright David Lebowitz - Morgan Stanley Etzer Darout - Guggenheim Alec Stranahan - Bank of America Anupam Rama - JPMorgan Peter Lawson - Barclays ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

mAbs herapeutics, Inc. Company Presentation September 2020 Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans a ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2020 Earnings Conference Call August 7, 2020 9:00 AM ET Company Participants Thomas Gad - Founder, Chairman, President & Head, Business Development & Strategy Claus Moller - Chief Executive Officer Bo Kruse - Executive Vice President & Chief Financial Office Conference Call Participants Alec Stranahan - Bank of America Merrill Lynch Etzer Darout - Guggenheim Securities, LLC Robert Burns - H.C. Wainwright & Co., LLC David Lebowitz - Morgan Stanley Peter Lawson - Bar ...

mAbs herapeutics, Inc. Company Presentation August 2020 Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and ...